Panzyga Study

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

4 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Immune Thrombocytopenia (ITP) is a blood disorder in which the immune system produces antibodies that attack and destroy the body's own blood platelets. The Panzyga Study is looking at a potential medicine (experimental drug) to see if it can result in increasing platelet counts and may potentially treat ITP. You will be infused with the experimental drug once or twice during the treatment period and will be followed up for 32 days. Testing will include blood tests, urine tests, pregnancy tests and physical exams. You may be able to take part in the study if you are below 18 years of age and have been diagnosed with chronic ITP.

Eligibility & Criteria

IRB #:
19-016318
Official Title:
Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients with Chronic Immune Thrombocytopenia (ITP)
Study Phase:
Phase IV
Eligible Age Range:
1 - 17 1/2 Years
Gender:
All
Study Categories:

Visit Criteria

Your participation will last for about a month and will involve 7 or 9 study visits. You will receive the study drug, Panzyga, once or twice. It will be given through an intravenous infusion (IV).

Leader

Kandace Gollomp, MD